1-6 of 6
Authors: Lerato Mohapi
Journal Article
1-Year Incidence of Tuberculosis Infection and Disease Among Household Contacts of Rifampin- and Multidrug-Resistant Tuberculosis Free
Clinical Infectious Diseases, Volume 77, Issue 6, 15 September 2023, Pages 892–900, https://doi.org/10.1093/cid/ciad301
Published: 25 May 2023
Journal Article
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349) Get access
Clinical Infectious Diseases, Volume 76, Issue 3, 1 February 2023, Pages e580–e589, https://doi.org/10.1093/cid/ciac707
Published: 30 August 2022
Journal Article
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine Free
Clinical Infectious Diseases, Volume 75, Issue 4, 15 August 2022, Pages 560–566, https://doi.org/10.1093/cid/ciab1037
Published: 16 December 2021
Journal Article
Willingness to Take Multidrug-resistant Tuberculosis (MDR-TB) Preventive Therapy Among Adult and Adolescent Household Contacts of MDR-TB Index Cases: An International Multisite Cross-sectional Study Free
Clinical Infectious Diseases, Volume 70, Issue 3, 1 February 2020, Pages 436–445, https://doi.org/10.1093/cid/ciz254
Published: 28 March 2019
Journal Article
Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease Free
Clinical Infectious Diseases, Volume 70, Issue 3, 1 February 2020, Pages 425–435, https://doi.org/10.1093/cid/ciz235
Published: 28 March 2019
Journal Article
Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention Free
Clinical Infectious Diseases, Volume 61, Issue 8, 15 October 2015, Pages 1322–1327, https://doi.org/10.1093/cid/civ464
Published: 16 June 2015
